Novartis Says Kisqali Shows Meaningful Overall Survival in Early Breast Cancer
Novartis said Kisqali showed clinically meaningful overall survival in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence.
Novartis said Kisqali showed clinically meaningful overall survival in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence.